Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV).

Suppr

超能文献

作者信息

Oie S, Jacobson M A, Abrams D I

出版信息

J Acquir Immune Defic Syndr (1988). 1993 May;6(5):531-3.

PMID:8097790

Abstract

摘要

相似文献

Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV).

J Acquir Immune Defic Syndr (1988). 1993 May;6(5):531-3.

Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.接受齐多夫定治疗的艾滋病及艾滋病相关综合征患者生存的替代标志物。

BMJ. 1991 Jan 12;302(6768):73-8. doi: 10.1136/bmj.302.6768.73.

Surrogate markers for AIDS treatment.

Nurs Times. 1991;87(22):49.

Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy.血清可溶性CD8、新蝶呤、β2-微球蛋白和p24抗原水平作为接受齐多夫定治疗的艾滋病儿童疾病进展的指标。

AIDS. 1993 Mar;7(3):369-73. doi: 10.1097/00002030-199303000-00010.

Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).

J Clin Lab Anal. 1991;5(6):396-8. doi: 10.1002/jcla.1860050606.

Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events.

J Acquir Immune Defic Syndr (1988). 1994 Sep;7(9):931-9.

Effect of azidothymidine (AZT) on HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD8, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS.

Int J Immunopharmacol. 1990;12(7):737-41. doi: 10.1016/0192-0561(90)90036-m.

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.1型人类免疫缺陷病毒感染中细胞和血清学标志物的预后价值。

N Engl J Med. 1990 Jan 18;322(3):166-72. doi: 10.1056/NEJM199001183220305.

Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.一组艾滋病毒阳性患者在接受齐多夫定12个月治疗期间观察到的不同临床、免疫学和血清学参数的变化情况。

Boll Ist Sieroter Milan. 1990 Jun;69(2):423-30.

Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.HIV-1感染中替代标志物、病毒载量与疾病进展之间的相关性。

J Acquir Immune Defic Syndr (1988). 1994 Oct;7(10):1028-33.

引用本文的文献

In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.AIC292，一种新型 HIV-1 非核苷类逆转录酶抑制剂的体外和体内活性。

Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9. doi: 10.1128/AAC.01377-13. Epub 2013 Aug 19.

Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.在包括在 ANRS 107 试验中的感染 HIV 的患者中，α-1 糖蛋白酸浓度和变异体对阿扎那韦药代动力学的影响。

Antimicrob Agents Chemother. 2010 Feb;54(2):614-9. doi: 10.1128/AAC.00797-09. Epub 2009 Dec 7.

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.TMC278，一种新一代非核苷类逆转录酶抑制剂（NNRTI），对野生型和 NNRTI 耐药的 HIV-1 均具有活性。

Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23.

Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.HIV感染成人中洛匹那韦和利托那韦的同步群体药代动力学模型。

Clin Pharmacokinet. 2008;47(10):681-92. doi: 10.2165/00003088-200847100-00005.

Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma.茚地那韦和沙奎那韦在配对的母体和脐带血浆中的差异蛋白结合

Br J Clin Pharmacol. 2007 Mar;63(3):315-21. doi: 10.1111/j.1365-2125.2006.02766.x. Epub 2006 Sep 19.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.TMC125，一种新型的下一代非核苷类逆转录酶抑制剂，对耐非核苷类逆转录酶抑制剂的1型人类免疫缺陷病毒具有活性。

Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6. doi: 10.1128/AAC.48.12.4680-4686.2004.

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.在HIV阳性受试者的给药间隔期间，沙奎那韦和茚地那韦的游离百分比保持恒定。

Br J Clin Pharmacol. 2002 Sep;54(3):262-8. doi: 10.1046/j.1365-2125.2002.01663.x.

Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.接受非核苷类逆转录酶抑制剂依非韦伦治疗的HIV阳性患者中，美沙酮的药代动力学。

Br J Clin Pharmacol. 2002 Feb;53(2):212-4. doi: 10.1046/j.0306-5251.2001.01539.x.

In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.α1-酸性糖蛋白对人免疫缺陷病毒蛋白酶抑制剂安普那韦药代动力学的体内作用

Antimicrob Agents Chemother. 2001 Mar;45(3):852-6. doi: 10.1128/AAC.45.3.852-856.2001.

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.多次口服给药后人类免疫缺陷病毒蛋白酶抑制剂安普那韦的药代动力学和药效学研究。

Antimicrob Agents Chemother. 2001 Jan;45(1):30-7. doi: 10.1128/AAC.45.1.30-37.2001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验